Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026)
Tilray Brands (TLRY) posted Income from Non-Controlling Interests of $1.6 million for Q1 2026, down 20.11% on a QoQ basis from $1.9 million in Q4 2025, and up 137.99% year-over-year from $654217.8 in Q1 2025.
Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Tilray Brands' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 137.99% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $11.0 million (down 33.48% YoY) and the FY2025 annual result came in at $5.4 million, down 76.16% from the prior year.
- Income from Non-Controlling Interests was $1.6 million for Q1 2026 at Tilray Brands, down from $1.9 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $39.6 million in Q2 2022 and bottomed at -$12.3 million in Q1 2024.
- A 5-year average of $6.1 million and a median of $2.8 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests jumped 688.99% — and 2024, when it slumped 704.85%.
- Tilray Brands' Income from Non-Controlling Interests stood at $7.8 million in 2022, then plunged by 63.91% to $2.8 million in 2023, then tumbled by 128.99% to -$819000.0 in 2024, then jumped by 337.97% to $1.9 million in 2025, then slipped by 20.11% to $1.6 million in 2026.
- Business Quant data shows TLRY's Income from Non-Controlling Interests at $1.6 million in Q1 2026, $1.9 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 1.56 Mn |
| Nov 30, 2025 | 1.95 Mn |
| Aug 31, 2025 | 1.81 Mn |
| May 31, 2025 | 5.66 Mn |
| Feb 28, 2025 | -4.10 Mn |
| Nov 30, 2024 | -819,000.00 |
| Aug 31, 2024 | 5.05 Mn |
| May 31, 2024 | 16.37 Mn |
| Feb 29, 2024 | -12.28 Mn |
| Nov 30, 2023 | 2.83 Mn |
| Aug 31, 2023 | 15.66 Mn |
| May 31, 2023 | 18.89 Mn |
| Feb 28, 2023 | -1.53 Mn |
| Nov 30, 2022 | 7.83 Mn |
| Aug 31, 2022 | 7.69 Mn |
| May 31, 2022 | 39.57 Mn |
| Feb 28, 2022 | -2.93 Mn |
| Nov 30, 2021 | 6.00 Mn |
| Aug 31, 2021 | 7.05 Mn |
| May 31, 2021 | -6.72 Mn |